ProQR Therapeutics Statistics
Share Statistics
ProQR Therapeutics has 105.21M
shares outstanding. The number of shares has increased by 28.84%
in one year.
Shares Outstanding | 105.21M |
Shares Change (YoY) | 28.84% |
Shares Change (QoQ) | 1.95% |
Owned by Institutions (%) | 54.38% |
Shares Floating | n/a |
Failed to Deliver (FTD) Shares | 162,156 |
FTD / Avg. Volume | 29.81% |
Short Selling Information
The latest short interest is 825.45K, so 0.78% of the outstanding
shares have been sold short.
Short Interest | 825.45K |
Short % of Shares Out | 0.78% |
Short % of Float | 1% |
Short Ratio (days to cover) | 1.45 |
Valuation Ratios
The PE ratio is -7.53 and the forward
PE ratio is -3.44.
ProQR Therapeutics's PEG ratio is
2.63.
PE Ratio | -7.53 |
Forward PE | -3.44 |
PS Ratio | 11.05 |
Forward PS | 2 |
PB Ratio | 2.36 |
P/FCF Ratio | -5.53 |
PEG Ratio | 2.63 |
Financial Ratio History Enterprise Valuation
Currently the Enterprise Value (EV) is not available for ProQR Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.95,
with a Debt / Equity ratio of 0.19.
Current Ratio | 3.95 |
Quick Ratio | 3.95 |
Debt / Equity | 0.19 |
Debt / EBITDA | -0.71 |
Debt / FCF | -0.46 |
Interest Coverage | -28.29 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $113,885.54 |
Profits Per Employee | $-167,246.99 |
Employee Count | 166 |
Asset Turnover | 0.11 |
Inventory Turnover | n/a |
Taxes
Income Tax | -197K |
Effective Tax Rate | 0.7% |
Stock Price Statistics
The stock price has increased by -1% in the
last 52 weeks. The beta is 0.24, so ProQR Therapeutics's
price volatility has been higher than the market average.
Beta | 0.24 |
52-Week Price Change | -1% |
50-Day Moving Average | 1.64 |
200-Day Moving Average | 2.32 |
Relative Strength Index (RSI) | 72.71 |
Average Volume (20 Days) | 543,879 |
Income Statement
In the last 12 months, ProQR Therapeutics had revenue of 18.91M
and earned -27.76M
in profits. Earnings per share was -0.34.
Revenue | 18.91M |
Gross Profit | 18.91M |
Operating Income | -30.47M |
Net Income | -27.76M |
EBITDA | -24.12M |
EBIT | -26.88M |
Earnings Per Share (EPS) | -0.34 |
Full Income Statement Balance Sheet
The company has 149.41M in cash and 17.22M in
debt, giving a net cash position of 132.19M.
Cash & Cash Equivalents | 149.41M |
Total Debt | 17.22M |
Net Cash | 132.19M |
Retained Earnings | -427.16M |
Total Assets | 167.96M |
Working Capital | 114.94M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -36.39M
and capital expenditures -1.42M, giving a free cash flow of -37.81M.
Operating Cash Flow | -36.39M |
Capital Expenditures | -1.42M |
Free Cash Flow | -37.81M |
FCF Per Share | -0.46 |
Full Cash Flow Statement Margins
Gross margin is 100%, with operating and profit margins of -161.18% and -146.86%.
Gross Margin | 100% |
Operating Margin | -161.18% |
Pretax Margin | -147.9% |
Profit Margin | -146.86% |
EBITDA Margin | -127.6% |
EBIT Margin | -161.18% |
FCF Margin | -200.01% |